Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LinkDoc’s US Listing In Jeopardy Following China's New Data Security Requirements

Executive Summary

The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.

You may also be interested in...



China’s Threat To Global Medtech Markets Is Rising

China’s economic might and industrial drive are being felt increasingly in medtech, and the just-released 14th five-year plan will give Chinese manufacturers more support for expansion, both at home and in overseas markets. Should EU and US industries be worried?

Massive Selloff Hits US, HK-Listed China Health Cos, Clouds Sunny Prospects

Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.

From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light

Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.

Topics

UsernamePublicRestriction

Register

MT144277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel